Cancer-associated fibroblasts-heroes or villains?
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
13
06
2018
accepted:
22
05
2019
revised:
19
05
2019
pubmed:
11
7
2019
medline:
11
3
2020
entrez:
11
7
2019
Statut:
ppublish
Résumé
Cancer-associated fibroblasts (CAFs) were originally presumed to represent a homogeneous population uniformly driving tumorigenesis, united by their morphology and peritumoural location. Our understanding of CAFs has since been shaped by sophisticated in vitro and in vivo experiments, pathological association and, more recently, ablation, and it is now widely appreciated that CAFs form a group of highly heterogeneous cells with no single overarching marker. Studies have demonstrated that the CAF population contains different subtypes based on the expression of marker proteins with the capacity to promote or inhibit cancer, with their biological role as accomplices or adversaries dependent on many factors, including the cancer stage. So, while CAFs have been endlessly shown to promote the growth, survival and spread of tumours via improvements in functionality and an altered secretome, they are also capable of retarding tumorigenesis via largely unknown mechanisms. It is important to reconcile these disparate results so that the functions of, or factors produced by, tumour-promoting subtypes can be specifically targeted to improve cancer patient outcomes. This review will dissect out CAF complexity and CAF-directed cancer treatment strategies in order to provide a case for future, rational therapies.
Identifiants
pubmed: 31289350
doi: 10.1038/s41416-019-0509-3
pii: 10.1038/s41416-019-0509-3
pmc: PMC6738083
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
293-302Références
Koliaraki, V., Pallangyo, C. K., Greten, F. R. & Kollias, G. Mesenchymal cells in colon cancer. Gastroenterology 152, 964–979 (2017).
pubmed: 28111227
doi: 10.1053/j.gastro.2016.11.049
Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).
pubmed: 27550820
doi: 10.1038/nrc.2016.73
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2001).
doi: 10.1038/nature01322
Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986).
pubmed: 3537791
doi: 10.1056/NEJM198612253152606
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320–329 (2015).
pubmed: 25706628
doi: 10.1038/ng.3225
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A. et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312–319 (2015).
pubmed: 25706627
doi: 10.1038/ng.3224
Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Soneson, C. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).
pubmed: 26457759
pmcid: 4636487
doi: 10.1038/nm.3967
Ozdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C., Simpson, T. R. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).
pubmed: 24856586
pmcid: 4180632
doi: 10.1016/j.ccr.2014.04.005
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747 (2014).
pubmed: 24856585
pmcid: 4096698
doi: 10.1016/j.ccr.2014.04.021
Li, H., Courtois, E. T., Sengupta, D., Tan, Y., Chen, K. H., Goh, J. J. et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49, 708–718 (2017).
pubmed: 28319088
doi: 10.1038/ng.3818
pmcid: 28319088
Sugimoto, H., Mundel, T. M., Kieran, M. W. & Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol, Ther, 5, 1640–1646 (2014).
doi: 10.4161/cbt.5.12.3354
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Erez, N., Truitt, M., Olson, P., Arron, S. T. & Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kB-dependent manner. Cancer Cell 17, 135–147 (2010).
pubmed: 20138012
doi: 10.1016/j.ccr.2009.12.041
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330, 827–830 (2010).
pubmed: 21051638
doi: 10.1126/science.1195300
Liao, D., Luo, Y., Markowitz, D., Xiang, R. & Reisfeld, R. A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4, https://doi.org/10.1371/journal.pone.0007965 (2009).
pubmed: 19956757
pmcid: 2775953
doi: 10.1371/journal.pone.0007965
Li, T., Yang, Y., Hua, X., Wang, G., Liu, W., Jia, C. et al. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 318, 154–161 (2012).
pubmed: 22182446
doi: 10.1016/j.canlet.2011.12.020
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
pubmed: 29443960
pmcid: 6028240
doi: 10.1038/nature25501
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M. et al. TGF beta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538–543 (2018).
pubmed: 29443964
doi: 10.1038/nature25492
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S. et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32, 654–668 (2017).
pubmed: 29136508
pmcid: 5827952
doi: 10.1016/j.ccell.2017.10.005
Kugeratski, F. G., Atkinson, S. J., Neilson, L. J., Lilla, S., Knight, J. R. P., Serneels, J. et al. Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Sci. Signal. 12, https://doi.org/10.1126/scisignal.aan8247 (2019).
pubmed: 30723174
doi: 10.1126/scisignal.aan8247
Madsen, C. D., Pedersen, J. T., Venning, F. A., Singh, L. B., Moeendarbary, E., Charras, G. et al. Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. EMBO Rep. 16, 1394–1408 (2015).
pubmed: 26323721
pmcid: 4662858
doi: 10.15252/embr.201540107
Zhou, Y., Ren, H., Dai, B., Li, J., Shang, L., Huang, J. et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J. Exp. Clin. Cancer Res. 37, https://doi.org/10.1186/s13046-018-0965-2 (2018).
pubmed: 30591064
pmcid: 6307162
doi: 10.1186/s13046-018-0965-2
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G. et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984–4001 (2009).
pubmed: 19923890
doi: 10.4161/cc.8.23.10238
Martinez-Outschoorn, U. E., Prisco, M., Ertel, A., Tsirigos, A., Lin, Z., Pavlides, S. et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 10, 1271–1286 (2011).
pubmed: 21512313
pmcid: 3117136
doi: 10.4161/cc.10.8.15330
Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R. G., Chiavarina, B. et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9, 3506–3514 (2010).
pubmed: 20818174
pmcid: 3047616
doi: 10.4161/cc.9.17.12731
Sakamoto, A., Kunou, S., Shimada, K., Tsunoda, M., Aoki, T., Iriyama, C. et al. Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells. Cancer Sci. 110, 269–278 (2019).
pubmed: 30426593
doi: 10.1111/cas.13873
Zhao, H., Yang, L., Baddour, J., Achreja, A., Bernard, V., Moss, T. et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife 5, https://doi.org/10.7554/eLife.10250 (2016).
pubmed: 26920219
pmcid: 4841778
doi: 10.7554/eLife.10250
Yan, W., Wu, X., Zhou, W., Fong, M. Y., Cao, M., Liu, J. et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 20, 597–609 (2018).
pubmed: 29662176
pmcid: 5920728
doi: 10.1038/s41556-018-0083-6
Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392–401 (2006).
pubmed: 16572188
doi: 10.1038/nrc1877
De Wever, O. & Mareel, M. Role of tissue stroma in cancer cell invasion. J. Pathol. 200, 429–447 (2003).
pubmed: 12845611
doi: 10.1002/path.1398
pmcid: 12845611
Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422–433 (2003).
pubmed: 12778132
doi: 10.1038/nrc1094
pmcid: 12778132
Kuchnio, A., Moens, S., Bruning, U., Kuchnio, K., Cruys, B., Thienpont, B. et al. The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts. Cell Rep. 12, 992–1005 (2015).
pubmed: 26235614
doi: 10.1016/j.celrep.2015.07.010
pmcid: 26235614
Pickup, M. W., Laklai, H., Acerbi, I., Owens, P., Gorska, A. E., Chytil, A. et al. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-beta-deficient mouse mammary carcinomas. Cancer Res. 73, 5336–5346 (2013).
pubmed: 23856251
pmcid: 3766496
doi: 10.1158/0008-5472.CAN-13-0012
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009).
pubmed: 19931152
pmcid: 2788004
doi: 10.1016/j.cell.2009.10.027
Lee, H. O., Mullins, S. R., Franco-Barraza, J., Valianou, M., Cukierman, E. & Cheng, J. D. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11, https://doi.org/10.1186/1471-2407-11-245 (2011).
pubmed: 21668992
pmcid: 3141768
doi: 10.1186/1471-2407-11-245
Miyazaki, K., Oyanagi, J., Hoshino, D., Togo, S., Kumagai, H. & Miyagi, Y. Cancer cell migration on elongate protrusions of fibroblasts in collagen matrix. Sci. Rep. 9, https://doi.org/10.1038/s41598-018-36646-z (2019).
pubmed: 30670761
pmcid: 6342997
doi: 10.1038/s41598-018-36646-z
Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K. et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9, 1392–1400 (2007).
pubmed: 18037882
doi: 10.1038/ncb1658
pmcid: 18037882
Labernadie, A., Kato, T., Brugues, A., Serra-Picamal, X., Derzsi, S., Arwert, E. et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat. Cell Biol. 19, 224–237 (2017).
pubmed: 28218910
pmcid: 5831988
doi: 10.1038/ncb3478
Vermeulen, L., Todaro, M., De Sousa Mello, F., Sprick, M. R., Kemper, K., Perez Alea, M. et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl Acad. Sci. USA 106, 13427–13432 (2008).
doi: 10.1073/pnas.0805706105
Clevers, H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17, 313–319 (2011).
pubmed: 21386835
doi: 10.1038/nm.2304
pmcid: 21386835
Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S. et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 72, 2768–2779 (2012).
pubmed: 22472119
pmcid: 3367125
doi: 10.1158/0008-5472.CAN-11-3567
Todaro, M., Gaggianesi, M., Catalano, V., Benfante, A., Iovino, F., Biffoni, M. et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342–356 (2014).
pubmed: 24607406
doi: 10.1016/j.stem.2014.01.009
pmcid: 24607406
Xiong, S., Wang, R., Chen, Q., Luo, J., Wang, J., Zhao, Z. et al. Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signalling. Am. J. Cancer Res. 8, 302–316 (2018).
pubmed: 29511600
pmcid: 5835697
Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L. et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 70, 6945–6956 (2010).
pubmed: 20699369
doi: 10.1158/0008-5472.CAN-10-0785
pmcid: 20699369
Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420–1428 (2009).
pubmed: 19487818
pmcid: 2689101
doi: 10.1172/JCI39104
Ebbing, E. A., van der Zalm, A. P., Steins, A., Creemers, A., Hermsen, S., Rentenaar, R. et al. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proc. Natl Acad. Sci. USA 116, 2237–2242 (2019).
pubmed: 30670657
doi: 10.1073/pnas.1820459116
pmcid: 30670657
Brabletz, T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 22, 699–701 (2012).
pubmed: 23238008
doi: 10.1016/j.ccr.2012.11.009
pmcid: 23238008
Duda, D. G., Duyverman, A. M., Kohno, M., Snuderl, M., Steller, E. J., Fukumura, D. et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA 107, 21677–21682 (2010).
pubmed: 21098274
doi: 10.1073/pnas.1016234107
pmcid: 21098274
Gao, Q., Yang, Z., Xu, S., Li, X., Yang, X., Jin, P. et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J. Exp. Med. 216, 688–703 (2019).
pubmed: 30710055
pmcid: 6400537
doi: 10.1084/jem.20180765
De Wever, O., Van Bockstal, M., Mareel, M., Hendrix, A. & Bracke, M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin Cancer Biol. 25, 33–46 (2014).
pubmed: 24406210
doi: 10.1016/j.semcancer.2013.12.009
pmcid: 24406210
Del Pozo Martin, Y., Park, D., Ramachandran, A., Ombrato, L., Calvo, F., Chakravarty, P. et al. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell Rep. 13, 2456–2469 (2015).
pubmed: 26670048
pmcid: 4695340
doi: 10.1016/j.celrep.2015.11.025
Malanchi, I., Santamaria-Martinez, A., Susanto, E., Peng, H., Lehr, H. A., Delaloye, J. F. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85–89 (2011).
pubmed: 22158103
doi: 10.1038/nature10694
pmcid: 22158103
Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA 72, 3585–3589 (1975).
pubmed: 1059147
doi: 10.1073/pnas.72.9.3585
pmcid: 1059147
Stoker, M. G., Shearer, M. & O’Neill, C. Growth inhibition of polyoma-transformed cells by contact with static normal fibroblasts. J. Cell Sci. 1, 297–310 (1966).
pubmed: 4291022
pmcid: 4291022
Dotto, G. P., Weinberg, R. A. & Ariza, A. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc. Natl Acad. Sci. USA 85, 6389–6393 (1988).
pubmed: 2457913
doi: 10.1073/pnas.85.17.6389
pmcid: 2457913
Djurec, M., Grana, O., Lee, A., Troule, K., Espinet, E., Cabras, L. et al. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc. Natl Acad. Sci. USA 115, E1147–E1156 (2018).
pubmed: 29351990
doi: 10.1073/pnas.1717802115
pmcid: 29351990
Madar, S., Brosh, R., Buganim, Y., Ezra, O., Goldstein, I., Solomon, H. et al. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis 30, 20–27 (2009).
pubmed: 18842679
doi: 10.1093/carcin/bgn232
pmcid: 18842679
Lim, P. K., Bliss, S. A., Patel, S. A., Taborga, M., Dave, M. A., Gregory, L. A. et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 71, 1550–1560 (2011).
pubmed: 21343399
doi: 10.1158/0008-5472.CAN-10-2372
pmcid: 21343399
Amakye, D., Jagani, Z. & Dorsch, M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19, 1410–1422 (2013).
pubmed: 24202394
doi: 10.1038/nm.3389
pmcid: 24202394
Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffery, T. et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14, 5995–6004 (2008).
pubmed: 18829478
pmcid: 2782957
doi: 10.1158/1078-0432.CCR-08-0291
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D. et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).
pubmed: 19460966
pmcid: 2998180
doi: 10.1126/science.1171362
Gerling, M., Buller, N. V., Kirn, L. M., Joost, S., Frings, O., Englert, B. et al. Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth. Nat. Commun. 7, https://doi.org/10.1038/ncomms12321 (2016).
pubmed: 27492255
pmcid: 4980446
doi: 10.1038/ncomms12321
Chen, S., Giannakou, A., Wyman, S., Gruzas, J., Golas, J., Zhong, W. et al. Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture. Proc. Natl Acad. Sci. USA 115, E11671–E11680 (2018).
pubmed: 30487219
doi: 10.1073/pnas.1803718115
pmcid: 30487219
Costanza, B., Umelo, I. A., Bellier, J., Castronovo, V. & Turtoi, A. Stromal modulators of TGF-beta in cancer. J. Clin. Med. 6, https://doi.org/10.3390/jcm6010007 (2017).
Maris, P., Blomme, A., Palacios, A. P., Costanza, B., Bellahcene, A., Bianchi, E. et al. Asporin is a fibroblast-derived TGF-beta1 inhibitor and a tumor suppressor associated with good prognosis in breast cancer. PLoS Med. 12, https://doi.org/10.1371/journal.pmed.1001871 (2015).
pubmed: 26327350
pmcid: 4556693
doi: 10.1371/journal.pmed.1001871
Chang, P. H., Hwang-Verslues, W. W., Chang, Y. C., Chen, C. C., Hsiao, M., Jeng, Y. M. et al. Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/beta-catenin pathway. Cancer Res. 72, 4652–4661 (2012).
pubmed: 22826604
pmcid: 3445732
doi: 10.1158/0008-5472.CAN-12-0877
Marlow, R., Strickland, P., Lee, J. S., Wu, X., Pebenito, M., Binnewies, M. et al. SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res. 68, 7819–7827 (2008).
pubmed: 18829537
pmcid: 3075571
doi: 10.1158/0008-5472.CAN-08-1357
Lo, A., Li, C. P., Buza, E. L., Blomberg, R., Govindaraju, P., Avery, D. et al. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight 2, https://doi.org/10.1172/jci.insight.92232 (2017).
Wen, Y., Wang, C. T., Ma, T. T., Li, Z. Y., Zhou, L. N., Mu, B. et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101, 2325–2332 (2010).
pubmed: 20804499
doi: 10.1111/j.1349-7006.2010.01695.x
pmcid: 20804499
Lo, A., Wang, L. S., Scholler, J., Monslow, J., Avery, D., Newick, K. et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 75, 2800–2810 (2015).
pubmed: 25979873
pmcid: 4506263
doi: 10.1158/0008-5472.CAN-14-3041
Adams, S., Miller, G. T., Jesson, M. I., Watanabe, T., Jones, B. & Wallner, B. P. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 64, 5471–5480 (2004).
pubmed: 15289357
doi: 10.1158/0008-5472.CAN-04-0447
Narra, K., Mullins, S. R., Lee, H.-O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V. J. et al. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol. Ther. 6, 1691–1699 (2007).
pubmed: 18032930
doi: 10.4161/cbt.6.11.4874
pmcid: 18032930
Hofheinz, R. D., al-Batran, S. E., Hartmann, F., Hartung, G., Jäger, D., Renner, C. et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26, 44–48 (2003).
pubmed: 12624517
pmcid: 12624517
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L. et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172, 841–856 (2018).
pubmed: 29395328
doi: 10.1016/j.cell.2018.01.009
pmcid: 29395328
Boesch, M., Onder, L., Cheng, H. W., Novkovic, M., Morbe, U., Sopper, S. et al. Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. Oncoimmunology 7, https://doi.org/10.1080/2162402X.2017.1414129 (2018).
pubmed: 29632733
pmcid: 5889213
doi: 10.1080/2162402X.2017.1414129
Duluc, C., Moatassim-Billah, S., Chalabi-Dchar, M., Perraud, A., Samain, R., Breibach, F. et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol. Med. 7, 735–753 (2015).
pubmed: 25834145
pmcid: 4459815
doi: 10.15252/emmm.201404346
Thongchot, S., Ferraresi, A., Vidoni, C., Loilome, W., Yongvanit, P., Namwat, N. et al. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. Cancer Lett. 430, 160–171 (2018).
pubmed: 29802929
doi: 10.1016/j.canlet.2018.05.031
pmcid: 29802929
Radisky, E. S., Raeeszadeh-Sarmazdeh, M. & Radisky, D. C. Therapeutic potential of matrix metalloproteinase inhibition in breast cancer. J. Cell Biochem. 118, 3531–3548 (2017).
pubmed: 28585723
pmcid: 5621753
doi: 10.1002/jcb.26185
Catenacci, D. V., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R. et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J. Clin. Oncol. 33, 4284–4292 (2015).
pubmed: 26527777
pmcid: 4678179
doi: 10.1200/JCO.2015.62.8719
Kim, E. J., Sahai, V., Abel, E. V., Griffith, K. A., Greenson, J. K., Takebe, N. et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin. Cancer Res. 20, 5937–5945 (2014).
pubmed: 25278454
pmcid: 4254161
doi: 10.1158/1078-0432.CCR-14-1269
Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C. L. et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat. Commun. 9, https://doi.org/10.1038/s41467-018-05220-6 (2018).
pubmed: 30042390
pmcid: 6057940
doi: 10.1038/s41467-018-05220-6
Clocchiatti, A., Ghosh, S., Procopio, M. G., Mazzeo, L., Bordignon, P., Ostano, P. et al. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. J. Clin. Invest. 128, 5531–5548 (2018).
pubmed: 30395538
pmcid: 6264730
doi: 10.1172/JCI99159
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80–93 (2014).
pubmed: 25259922
pmcid: 4177038
doi: 10.1016/j.cell.2014.08.007
Schnittert, J., Heinrich, M. A., Kuninty, P. R., Storm, G. & Prakash, J. Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer. Cancer Lett. 420, 247–258 (2018).
pubmed: 29408203
doi: 10.1016/j.canlet.2018.01.072
Kim, D. J., Dunleavey, J. M., Xiao, L., Ollila, D. W., Troester, M. A., Otey, C. A. et al. Suppression of TGFbeta-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Br. J. Cancer 118, 1359–1368 (2018).
pubmed: 29695769
pmcid: 5959903
doi: 10.1038/s41416-018-0072-3
Takeda, S., Shigeyasu, K., Okugawa, Y., Yoshida, K., Mori, Y., Yano, S. et al. Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Cancer Lett. 444, 127–135 (2019).
pubmed: 30583079
doi: 10.1016/j.canlet.2018.12.009
Souma, K., Shichino, S., Hashimoto, S., Ueha, S., Tsukui, T., Nakajima, T. et al. Lung fibroblasts express a miR-19a-19b-20a sub-cluster to suppress TGF-beta-associated fibroblast activation in murine pulmonary fibrosis. Sci. Rep. 8, https://doi.org/10.1038/s41598-018-34839-0 (2018).
pubmed: 30413725
pmcid: 6226532
doi: 10.1038/s41598-018-34839-0
Melling, G. E., Flannery, S. E., Abidin, S. A., Clemmens, H., Prajapati, P., Hinsley, E. E. et al. A miRNA-145/TGF-beta1 negative feedback loop regulates the cancer-associated fibroblast phenotype. Carcinogenesis 39, 798–807 (2018).
pubmed: 29506142
doi: 10.1093/carcin/bgy032
Al-Harbi, B., Hendrayani, S. F., Silva, G. & Aboussekhra, A. Let-7b inhibits cancer-promoting effects of breast cancer-associated fibroblasts through IL-8 repression. Oncotarget 9, 17825–17838 (2018).
pubmed: 29707149
pmcid: 5915157
doi: 10.18632/oncotarget.24895
Saison-Ridinger, M., DelGiorno, K. E., Zhang, T., Kraus, A., French, R., Jaquish, D. et al. Reprogramming pancreatic stellate cells via p53 activation: a putative target for pancreatic cancer therapy. PLoS One 12, https://doi.org/10.1371/journal.pone.0189051 (2017).
pubmed: 29211796
pmcid: 5718507
doi: 10.1371/journal.pone.0189051
Albrengues, J., Bertero, T., Grasset, E., Bonan, S., Maiel, M., Bourget, I. et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat. Commun. 6, https://doi.org/10.1038/ncomms10204 (2015).
pubmed: 26667266
pmcid: 4682161
doi: 10.1038/ncomms10204
Hill, E. E., Kim, J. K., Jung, Y., Neeley, C. K., Pienta, K. J., Taichman, R. S. et al. Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J. Cell Biochem. 119, 8074–8083 (2018).
pubmed: 29380900
doi: 10.1002/jcb.26727
Ogier, C., Colombo, P. E., Bousquet, C., Canterel-Thouennon, L., Sicard, P., Garambois, V. et al. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett. 432, 227–236 (2018).
pubmed: 29935372
doi: 10.1016/j.canlet.2018.06.023
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
doi: 10.1056/NEJMoa1304369
Alvarez, R., Musteanu, M., Garcia-Garcia, E., Lopez-Casas, P. P., Megias, D., Guerra, C. et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 109, 926–933 (2013).
pubmed: 23907428
pmcid: 3749580
doi: 10.1038/bjc.2013.415
Li, M., Li, M., Yin, T., Shi, H., Wen, Y., Zhang, B. et al. Targeting of cancer-associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Mol. Med. Report 13, 2476–2484 (2016).
doi: 10.3892/mmr.2016.4868
Eager, R. M., Cunningham, C. C., Senzer, N. N., Stephenson, J. Jr., Anthony, S. P., O’Day, S. J. et al. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer 9, https://doi.org/10.1186/1471-2407-9-263 (2009).
pubmed: 19643020
pmcid: 2731782
doi: 10.1186/1471-2407-9-263
Eager, R. M., Cunningham, C. C., Senzer, N., Richards, D. A., Raju, R. N., Jones, B. et al. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin. Oncol. (R Coll Radiol) 21, 464–472 (2009).
doi: 10.1016/j.clon.2009.04.007
Owusu, B. Y., Galemmo, R., Janetka, J. & Klampfer, L. Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment. Cancers (Basel) 9, https://doi.org/10.3390/cancers9040035 (2017).
pmcid: 5406710
doi: 10.3390/cancers9040035
Wu, X., Chen, X., Zhou, Q., Li, P., Yu, B., Li, J. et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 335, 128–135 (2013).
pubmed: 23402812
doi: 10.1016/j.canlet.2013.02.002
Pant, S., Saleh, M., Bendell, J., Infante, J. R., Jones, S., Kurkjian, C. D. et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. Ann. Oncol. 25, 1416–1421 (2014).
pubmed: 24737778
doi: 10.1093/annonc/mdu157
Parikh, P. K. & Ghate, M. D. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur. J. Med. Chem. 143, 1103–1138 (2018).
pubmed: 29157685
doi: 10.1016/j.ejmech.2017.08.044
Brennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T. & Denmeade, S. R. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J. Natl Cancer Inst. 104, 1320–1334 (2012).
pubmed: 22911669
pmcid: 3529592
doi: 10.1093/jnci/djs336
Gao, W., Xiang, B., Meng, T. T., Liu, F. & Qi, X. R. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials 34, 4137–4149 (2013).
pubmed: 23453200
doi: 10.1016/j.biomaterials.2013.02.014
Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L. et al. Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors. Cancer Res. 77, 719–731 (2017).
pubmed: 27864344
doi: 10.1158/0008-5472.CAN-16-0866
Purcell, J. W., Tanlimco, S. G., Hickson, J. A., Fox, M., Sho, M., Durkin, L. et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res. 78, 4059–4072 (2018).
pubmed: 29764866
doi: 10.1158/0008-5472.CAN-18-0327
De Vlieghere, E., Gremonprez, F., Verset, L., Marien, L., Jones, C. J., De Craene, B. et al. Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells. Biomaterials 54, 148–157 (2015).
pubmed: 25907048
doi: 10.1016/j.biomaterials.2015.03.012
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518–527 (2008).
pubmed: 18438415
doi: 10.1038/nm1764
Navab, R., Strumpf, D., Bandarchi, B., Zhu, C., Pintilie, M., Ramnarine, V. R. et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc. Natl Acad. Sci. USA 108, 7160–7165 (2011).
pubmed: 21474781
doi: 10.1073/pnas.1014506108
Zou, B., Liu, X., Gong, Y., Cai, C., Li, P., Xing, S. et al. A novel 12-marker panel of cancer-associated fibroblasts involved in progression of hepatocellular carcinoma. Cancer Manag. Res. 10, 5303–5311 (2018).
pubmed: 30464627
pmcid: 6225911
doi: 10.2147/CMAR.S176152
Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V. et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15, 68–74 (2009).
pubmed: 19122658
doi: 10.1038/nm.1908
pmcid: 19122658
Brechbuhl, H. M., Finlay-Schultz, J., Yamamoto, T. M., Gillen, A. E., Cittelly, D. M., Tan, A. C. et al. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin. Cancer Res. 23, 1710–1721 (2017).
pubmed: 27702820
doi: 10.1158/1078-0432.CCR-15-2851
Ao, Z., Shah, S. H., Machlin, L. M., Parajuli, R., Miller, P. C., Rawal, S. et al. Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res. 75, 4681–4687 (2015).
pubmed: 26471358
doi: 10.1158/0008-5472.CAN-15-1633
Ohlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
pubmed: 28232471
pmcid: 5339682
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463–479 (2018).
pubmed: 29455927
doi: 10.1016/j.ccell.2018.01.011
pmcid: 29455927
Bartoschek, M., Oskolkov, N., Bocci, M., Lovrot, J., Larsson, C., Sommarin, M. et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat. Commun. 9, https://doi.org/10.1038/s41467-018-07582-3 (2018).
pubmed: 30514914
pmcid: 6279758
doi: 10.1038/s41467-018-07582-3
Cremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K., Woodruff, M. C. et al. FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors. Cancer Immunol Res. 6, 1472–1485 (2018).
pubmed: 30266714
doi: 10.1158/2326-6066.CIR-18-0098
Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y. et al. IL1-Induced JAK/STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282–301 (2019).
pubmed: 30366930
doi: 10.1158/2159-8290.CD-18-0710
Neuzillet, C., Tijeras-Raballand, A., Ragulan, C., Cros, J., Patil, Y., Martinet, M. et al. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J. Pathol. 248, 51–65 (2018).
pubmed: 30575030
pmcid: 6492001
doi: 10.1002/path.5224
Rai, A., Greening, D. W., Chen, M., Xu, R., Ji, H., Simpson, R. J. Exosomes derived from human primary and metastatic colorectal cancer cells contribute to functional heterogeneity of activated fibroblasts by reprogramming their proteome. Proteomics 19, https://doi.org/10.1002/pmic.201800148 (2018).
doi: 10.1002/pmic.201800148